On April 22, 2025 Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases and develop new antibody linker technologies, reported it will release promising new data for two of its pipeline products at the 2025 Annual American Association for Cancer Research (AACR) (Free AACR Whitepaper) meeting in Chicago, Illinois (Press release, Debiopharm, APR 22, 2025, View Source [SID1234652027]). Furthermore, a joint poster presentation with Oncodesign Services (www.oncodesign-services.com) will highlight the applicability of its antibody conjugation technology, AbYlink, in the preparation of conjugates for use in non-invasive preclinical imaging.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Comprehensive preclinical results will be presented for Debio 1562M, a next-generation Antibody-Drug Conjugate (ADC) targeting the cell surface glycoprotein CD37 soon to undergo first-in-human evaluation. Two preclinical data releases will be included in the poster display sessions for Debio 0123, a selective WEE1 kinase inhibitor disrupting the DNA-damage response (DDR) of cancer cells. The first data release shows how Debio 0123 can be used in combination with the PKMYT1 inhibitor lunresertib as a promising therapeutic strategy in ovarian and breast cancer. The company will also unveil new impactful findings stemming from its collaboration with Genialis, showing how machine learning has the potential to enhance the ability to predict responders to Debio 0123, thus further advancing the understanding and application of WEE1 biology and response to inhibitors.

Additionally, in the framework of a licensing agreement and a collaborative endeavor to support innovative research, Debiopharm and Oncodesign Services will present promising new data illustrating how AbYlink conjugation technology can facilitate the production of conjugates for use in preclinical research in cancer treatment.

"The pre-clinical results to be released during the AACR (Free AACR Whitepaper) are laying a solid foundation for future research," explained Angela Zubel, Chief Development Officer, Debiopharm. "The two drug research approaches of ADCs and DDR inhibition are harnessing novel modalities and targets with the potential to outsmart hard-to-treat liquid and solid tumors, revolutionizing patient outcomes. Our AbYlink technology demonstrates great potential in the context of antibody radio conjugates against cancer and shows promise for broader use and wider applications."

Session Title: Antibody-Based Cancer Therapeutic Agents
AACR 2025
Oral Presentation

Debiopharm compound

Title

Presenter

-Sun, April 27th

-Mini symposium: 3:35-3:50pm

-Abstract Presentation #: 1160

Debio 1562M

Debio 1562M, a 2nd generation ADC targeting CD37, shows high potency against AML and MDS and safe toxicological profile for future clinical development

Lisa Ivanschitz, Associate Principal Scientist, Debiopharm

Poster Session Title: DNA Damage Response and Modulation of DNA Repair 1
AACR 2025
Poster Presentation

Debiopharm compound

Title

Presenter

-Mon, April 28th

-Poster display: 2:00-5:00pm

-Abstract #2914

-Poster Section: 16

-Poster Board #: 21

Debio 0123

The WEE1 inhibitor Debio 0123 is synergistic with the PKMYT1 inhibitor lunresertib in preclinical models of ovarian and breast cancer

Luke Piggott, Principal Scientist, Debiopharm

Poster Session Title: Artificial Intelligence and Machine Learning for Therapeutic Election and Discovery
AACR 2025
Poster Presentation

Debiopharm compound

Title

Presenter

-Mon, April 28th

-Poster display: 2:00-5:00pm

-Abstract #3659

-Poster Section: 45

-Poster Board #: 21

Debio 0123

Biology-driven, machine learning-based development of a biomarker to predict response to WEE1 inhibitor Debio 0123

Kristian Urh, Genialis

Poster Session Title: Radiation Treatment Combinations for Tumors, Normal Tissue
AACR 2025
Poster Presentation

Debiopharm technology

Title

Presenter

-Mon, April 28th

-Poster display: 9:00am-12:00pm

-Abstract #1825

-Poster Section: 24

-Poster Board #: 11

AbYlink

Pharmacological evaluation of bioconjugated Trastuzumab using the AbYlink regio-selective conjugation technology in gastric cancer expressing HER2+

Eftychia Koumarianou, Head of pharmaco-imaging and molecular radiotherapy, Oncodesign Services

About DNA-Damage Repair (DDR)

When cells have damaged DNA, they need to undergo a repair process called DDR to be able to survive. Cancer cells rely a lot on DDR as they divide and grow uncontrollably. Inhibition of DDR, particularly in combination with other anticancer agents, prevents cancer cells from repairing their DNA, which ultimately activates a self-destruction program in cancer cells. DDR inhibitors such as Debio 0123, a WEE1 inhibitor from Debiopharm, are being tested in clinical and preclinical studies.